SLC2A1 and colorectal carcinoma: In conclusion, we identified DBI-2 that activated AMPK and inhibited the proliferation of CRC cells by targeting mitochondrial complex I. In vitro and in vivo experiments demonstrated that the combination of DBI-2 and BAY-876, a GLUT1 inhibitor, exhibited synergistic effects on CRC cells.